FORM PTO-1390 (Modified) (REV 11-2000) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER: 217323 PCT

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR): 09/926818

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/JP00/03860	JUNE 14, 2000	JUNE 21, 1999 (Earliest)

TITLE OF INVENTION

METHOD OF PRETREATMENT OF SAMPLE FOR QUANTITATING CHOLESTEROL AND METHOD FOR QUANTITATING CHOLESTEROL IN SPECIFIC LIPOPROTEINS BY USING THE SAME

APPLICANT(S) FOR DO/EO/US

Mitsuhiro NAKAMURA, et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include itens (5), (6), (9) and (24) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
   a. ☐ is attached hereto (required only if not communicated by the International Bureau).
   b. ☒ has been communicated by the International Bureau.
   c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
   a. ☒ is attached hereto.
   b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
   a. ☐ are attached hereto (required only if not communicated by the International Bureau).
   b. ☐ have been communicated by the International Bureau.
   c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
   d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☒ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☐ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

Request for Priority/Drawing (3 Sheets)/PCT/IB/304
PCT/IB/308/Form PTO 1449
Amended Sheets (Pages 7, 8, 8/1, 39, 40, 41/1)

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
09/926818	PCT/JP00/03860	217323US0PCT

24. The following fees are submitted:.

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

		CALCULATIONS PTO USE ONLY
☐	Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO $1040.00	
☒	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO $890.00	
☐	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO $740.00	
☐	International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) $710.00	
☐	International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) $100.00	

ENTER APPROPRIATE BASIC FEE AMOUNT =	**$890.00**	
Surcharge of **$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).	**$0.00**	

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	42 - 20 =	22	x $18.00	**$396.00**	
Independent claims	32 - 3 =	29	x $84.00	**$2,436.00**	
Multiple Dependent Claims **(check if applicable)**.			☐	**$0.00**	
TOTAL OF ABOVE CALCULATIONS =				**$3,722.00**	
☐ Applicant claims small entity status. See 37 CFR 1.27). The fees indicated above are reduced by 1/2.				**$0.00**	
SUBTOTAL =				**$3,722.00**	
Processing fee of **$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). +				**$0.00**	
TOTAL NATIONAL FEE =				**$3,722.00**	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) **(check if applicable).** ☐				**$0.00**	
TOTAL FEES ENCLOSED =				**$3,722.00**	
				Amount to be: refunded	$
				charged	$

a. ☒ A check in the amount of **$3,722.00** to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **15-0030** A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Surinder Sachar
Registration No. 34,423

22850

Surinder Sachar
SIGNATURE

Norman F. Oblon
NAME

24,618
REGISTRATION NUMBER

Dec. 21 2001
DATE

217323US-0PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF: :

MITSUHIRO NAKAMURA ET AL. :

SERIAL NO: NEW U.S. PCT APPLN. : ATTN: APPLICATION BRANCH
(Based on PCT/JP00/03860)

FILED: HEREWITH :

FOR: METHOD OF PRETREATMENT OF SAMPLE FOR QUANTITATING CHOLESTEROL AND METHOD FOR QUANTITATING CHOLESTEROL IN SPECIFIC LIPOPROTEINS BY USING THE SAME

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Prior to examination on the merits, please amend the above-identified application as follows.

IN THE CLAIMS

Please amend the claims as shown on the marked-up copy following this amendment to read as follows.

3. (Amended) A pretreatment method according to claim 1, wherein said enzyme is cholesterol oxidase or cholesterol dehydrogenase.

5. (Amended) A method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from the flufenamic acid, mefenamic

acid, 2,2',6',2''-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monesin or mevinlin, to act upon said sample with said lipoprotein contained therein to consume only said free cholesterol under conditions that said lipoproteins remain substantially unchanged; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only.

6. (Amended) A quantitation method according to claim 4, wherein said enzyme is cholesterol oxidase and/or cholesterol dehydrogenase.

7. (Amended) A quantitation method according to claim 4, wherein said specific lipoprotein is high density lipoprotein.

12. (Amended) A pretreatment agent according to claim 8, wherein said enzyme is cholesterol dehydrogenase or cholesterol oxidase.

Please add the following new claims.

38. (New) A pretreatment method according to claim 2, wherein said enzyme is cholesterol oxidase or cholesterol dehydrogenase.

39. (New) A quantitation method according to claim 5, wherein said enzyme is cholesterol oxidase and/or cholesterol dehydrogenase.

40. (New) A quantitation method according to claim 5, wherein said specific lipoprotein is high density lipoprotein.

41. (New) A pretreatment agent according to claim 9, wherein said enzyme is cholesterol dehydrogenase or cholesterol oxidase.

42. (New) A pretreatment agent according to claim 10, wherein said enzyme is cholesterol dehydrogenase or cholesterol oxidase.

REMARKS

Claims 1-42 are active in the present application. Claims 38-42 are new claims. Support for the new claims is found in the original claims. The original claims have been amended to remove multiple dependencies. No new matter is added. An action on the merits and allowance of claims is solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon
Attorney of Record
Registration No. 24,618

Daniel J. Pereira, Ph.D.
Registration No. 45,518

22850

(703) 413-3000
NFO/DJP/smi

I:\atty\SUKOS\217323US-pr.wpd

Marked-Up Copy
Serial No:

Amendment Filed on:
12-21-01

IN THE CLAIMS

Please amend the claims as follows.

--3. (Amended) A pretreatment method according to claim 1 [or 2], wherein said enzyme is cholesterol oxidase or cholesterol dehydrogenase.

5. (Amended) A method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from the flufenamic acid, mefenamic acid, 2,2',6',2''-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monesin or mevinlin, to act upon said sample with said lipoprotein contained therein to consume only said free cholesterol under conditions that said lipoproteins remain substantially unchanged; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only.

6. (Amended) A quantitation method according to claim 4 [or 5], wherein said enzyme is cholesterol oxidase and/or cholesterol dehydrogenase.

7. (Amended) A quantitation method according to [any one of claims 4-6] claim 4, wherein said specific lipoprotein is high density lipoprotein.

12. (Amended) A pretreatment agent according to [any one of claims 8-10] claim 8, wherein said enzyme is cholesterol dehydrogenase or cholesterol oxidase.

Claims 38-42 (New).--

DESCRIPTION

METHOD OF PRETREATMENT OF SAMPLE FOR QUANTITATING CHOLESTEROL AND METHOD FOR QUANTITATING CHOLESTEROL IN SPECIFIC LIPOPROTEINS BY USING THE SAME

Technical Field

This invention relates to a pretreatment method for accurately and efficiently discriminating and quantitating cholesterol, which exists in the specific lipoprotein fraction, by simple procedures while using a small amount of a sample, and also to a method for measuring cholesterol in the specific lipoprotein fraction by using the pretreatment method.

Background Art

Lipids such as cholesterol are complexed with apoproteins in blood to form lipoproteins. Depending on differences in physical properties, lipoproteins are classified into chylomicron, very low density lipoprotein (VLDL), low density lipoprotein (LDL), high density lipoprotein (HDL), and so on. Among these lipoproteins, LDL is known to be one of causative substances which induce arteriosclerosis, while HDL is known to show anti-arteriosclerotic activity.

Epidemiologically, the level of cholesterol in LDL is known to exhibit a positive correlation with the frequency of

onset of arteriosclerotic disease while the level of cholesterol in HDL is known to show an inverse correlation with the frequency of onset of arteriosclerotic disease. These days, measurements of cholesterol in LDL or HDL are, therefore, widely conducted for the prevention or diagnosis of ischemic heart diseases.

As methods known for the measurement of cholesterol in LDL or HDL, there are, for example, a method in which LDL or HDL is separated from other lipoproteins by ultracentrifugal separation and is then subjected to a cholesterol measurement; and another method in which subsequent to separation of LDL or HDL from other lipoproteins by electrophoresis, its lipid is stained, and the intensity of a developed color is measured. These methods are however not used practically, because they involve one or more problems in that procedures are intricate and many samples cannot be handled.

A method for the measurement of cholesterol in HDL, which is used at present in the field of clinical tests, is the precipitation method in which a precipitation reagent is added to a sample to agglutinate lipoproteins other than HDL, the resulting agglutinate is removed by centrifugation, and cholesterol in isolated supernatant which contains only HDL is then measured. This method is simpler compared with ultracentrifugation or electrophoresis, but due to the inclusion of the procedures to add the precipitation reagent and to perform the separation, requires each sample is a relatively large quantity, and involves a potential problem

of causing an analytical error. Furthermore, the entire analysis steps of this method can not be fully automated.

On the other hand, enzymatic methods have been studied for the fractional quantitation of cholesterol in HDL. Known methods include, for example, to conduct an enzymatic reaction in the presence of a bile acid salt and a nonionic surfactant (JP 63-126498 A). This method makes use of the fact that an enzymatic reaction proceeds in proportion to the concentration of cholesterol in LDL in an initial stage of the reaction and the subsequent reaction velocity is in proportion to the concentration of cholesterol in HDL. A problem however exists in accuracy because the reaction with the cholesterol in HDL and the reaction with cholesterol in other lipoproteins cannot be fully distinguished.

Also included in the known methods is to have lipoproteins other than HDL agglutinated in advance, to cause cholesterol in HDL alone to react enzymatically, and to inactivate the enzyme and at the same time, to redissolve the agglutinate, followed by the measurement of an absorbance (JP 6-242110 A). This method, however, requires at least three procedures to add reagents so that it can be applied only to particular automated analyzers, leading to a problem in a wide applicability. Further, this method is not satisfactory from the standpoint of damages to analytical equipment and disposal of the reagents because of the use of a salt at a high concentration upon redissolution of an agglutinate.

A still further method is also known (JP 9-299 A), which comprises causing, in a first reaction, cholesterol oxidase and cholesterol esterase to act upon lipoproteins other than HDL in the presence of a special surfactant and to have cholesterol, which is contained in such other lipoproteins, preferentially reacted, and then measuring cholesterol in HDL while inhibiting any reaction to cholesterol in lipoproteins other than HDL. This method, however, is considerably different from the present invention *inter alia* in that in the first reaction, the special surfactant, cholesterol oxidase and cholesterol esterase are required at the same time to put, outside the reaction system, both free cholesterol and esterified cholesterol in the lipoproteins other than HDL.

Further, Japanese Patent No. 2,600,065 discloses a method which makes combined use of a precipitation reagent, which is adapted to cause precipitation of lipoproteins other than HDL, and a cholesterol measuring reagent to measure cholesterol (HDL-C) in unprecipitated HDL. This method has practical utility when a modified enzyme is used as enzyme and α-cyclodextrin sulfate is used as a precipitation reagent. This method, however, also involves a problem in accuracy in that turbidity, which occurs as a result of the use of the precipitation reagent, interferes with the measurement system.

Concerning the measurement of HDL-C by a modified enzyme, "SEIBUTSU SHIRYO BUNSEKI (ANALYSIS OF BIOLOGICAL SAMPLES)", **19**(5), 305-320, which is considered to be a published paper

on the above-described patented method, discloses that, under the recognition of incapability of measurement of HDL-C in a serum of a hyperlipidemic patient by the modified enzyme due to a positive error (that is, to result in a higher value compared with that obtained by the precipitation method) induced when the modified enzyme is simply introduced into a reaction system, HDL-C was measured by using cyclodextrin sulfate, a polyanion, and magnesium chloride as a precipitation reagent for the avoidance of the positive error.

To reduce the influence of turbidity caused by a precipitation reagent in the above-described patented method, certain techniques are also known, including to make a surfactant exist concurrently (JP 8-116996 A), to use an antibody (JP 9-96637 A), and to employ a sugar compound (JP 7-301636 A). They, however, all require as a premise the inclusion of a reagent which induces formation of an agglutinate, so that it is fundamentally indispensable for them to use a precipitation reagent such as a polyanion.

The present inventors recently found that use of a substance, which acts upon the specific lipoprotein only, makes it possible to accurately quantitate cholesterol in the specific lipoprotein fraction without using a precipitation reagent, and filed patent applications (JP 9-244821). This method has an extremely high correlation with the conventional precipitation method, but compared in measurement values with the precipitation method, this method is recognized to have

a similar tendency as the above-described method reported in "SEIBUTSU SHIRYO BUNSEKI (ANALYSIS OF BIOLOGICAL SAMPLES)". To obtain data consistent with those obtained by the conventional precipitation method at medical institutions and the like, a polyanion or the like is added.

From the standpoint of the problem of a tarnish or the like on a cuvette and scattering of measurement values, however, it is not desired to add a polyanion or the like and to form a precipitate in a measurement system. Accordingly, it has been strongly desired to eliminate the precipitate from the system. Further, it is also economically unreasonable to use a polyanion or the like for making the resulting data consistent with those obtained by the precipitation method although the polyanion or the like is not needed from the standpoint of the principle of the measurement. Hence, there is also an outstanding desire for its solution.

An object of the present invention is, therefore, to provide a method, which can accurately and efficiently quantitate cholesterol in the specific lipoprotein fraction by simple procedures fundamentally without needing a polyanion or the like and is suitably applicable to various automated analyzers.

Disclosure of the invention

The present inventors proceeded with a thorough investigation for a cause which may be responsible for the

above-described problem reported in "SEIBUTSU SHIRYO BUNSEKI (ANALYSIS OF BIOLOGICAL SAMPLES)", that is, the problem that a value of cholesterol in the specific lipoprotein fraction as quantitated by using a substance which acts only upon a specific lipoprotein such as HDL becomes higher than the corresponding value as determined by the precipitation method; and came to a conclusion that even from non-HDL lipoproteins (LDL, VLDL and the like) the cholesterol of which is not supposed to be measured, a small amount of free cholesterol existing on their surfaces or in the vicinity of their surfaces is liberated to cause a positive error. Based on this finding, it has been found that a cholesterol value obtained by a quantitation method making use of a substance, which acts upon a specific lipoprotein only, becomes consistent with the corresponding value obtained by the precipitation method when the cholesterol value is measured after consuming only free cholesterol in advance under conditions that lipoproteins remain substantially unchanged, leading to the completion of the present invention.

Described specifically, the present invention provides a method for pretreating a sample, which contains various lipoproteins, prior to measuring cholesterol existing in specific one of the lipoproteins in the sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate,

to act upon the sample to consume only the free cholesterol in advance under conditions that the lipoproteins remain substantially unchanged.

The present invention also provides a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon the sample with the lipoprotein contained therein to consume only the free cholesterol under conditions that the lipoproteins remain substantially unchanged; and then measuring the cholesterol, which exists in the specific lipoprotein, by using a substance which acts upon the specific lipoprotein only.

Brief Description of the Figures

Fig. 1 is a diagram showing a correlation between the present invention in Example 1 and the precipitation method;

FIG. 2 is a diagram showing a correlation between the present invention in Example 2 and the precipitation method; and

FIG. 3 is a diagram showing effects of a reaction accelerator in Example 5.

Best Modes for Carrying Out the Invention

In the present invention, before measuring cholesterol

existing in a specific lipoprotein in a sample, an enzyme which acts upon free cholesterol as a substrate is caused to act, as pretreatment, upon the sample such that the free cholesterol is consumed.

As the enzyme which acts upon free cholesterol as a substrate, any enzyme can be used insofar as it acts upon free cholesterol as a substrate. Illustrative are cholesterol dehydrogenase and cholesterol oxidase. They can be of any

origins such as microorganism origins, animal origins or plant origins, and can also be those prepared by genetic engineering. Further, they can be either modified or unmodified chemically. The enzyme is generally used at 0.001 to 100 U/mL, with 0.1 to 100 U/mL being preferred.

No particular limitation is imposed on conditions under which the above-described enzyme, which acts upon free cholesterol as a substrate, is caused to act upon the sample, and conditions recommended for the enzyme can be used. It is however necessary to pay attention so that, during a stage in which the enzyme which acts upon free cholesterol as a substate is caused to act upon the sample, a reaction through which an esterified cholesterol is converted into free cholesterol does not take place. Namely, it is not important whether or not cholesterol esterase exists. What is needed is to maintain conditions such that cholesterol esterase is not allowed to act practically.

Along with the enzyme which acts upon free cholesterol as a substrate, a coenzyme can be used as needed. As the coenzyme, nicotinamide adenine dinucleotide or the like is usable. Such coenzymes can be used either singly or in combination. The amount to be used varies depending on the coenzyme. The coenzyme may be used at 0.001 to 100 U/mL, preferably at 0.1 to 100 U/mL, although no particular limitation is imposed thereon.

Concerning the enzyme which acts upon free cholesterol as a substrate and is used in the present invention, no limitation

is imposed on its origin as described above. Its concentration and the like can be chosen suitably to achieve desired performance and handling ease. Accordingly, if it is desired to have the pretreatment completed in a predetermined time, for example, it is only necessary to use the enzyme in a greater amount, and if it is conversely desired to save the enzyme, it is only necessary to make the pretreatment time longer.

In the case of a diagnostic reagent for exclusive use in measurements by automated analyzers, however, it is desired to meet both of the requirements at the same time. Namely, it is required to complete the pretreatment in a short time by using the enzyme in a small amount. In such a case, concurrent existence of a reaction accelerator selected from the below-described group in the pretreatment, which uses an enzyme which acts upon free cholesterol as a substrate, makes it possible to achieve desired performance with a reduced amount of the enzyme without making the pretreatment time longer.

Reaction accelerators usable for the above purpose can include, for example, flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin and mevinolin, including their salts and metal derivatives (aluminum derivatives and the like) wherever such salts and metal derivatives exist. Among these, flufenamic acid and mefenamic acid are known as non-steroidal anti-inflammatory drugs, and fusidic acid and monensin are known as antibiotics.

Upon using such a compound as a reaction accelerator, it is necessary to suitably choose its concentration and the like by taking into consideration its physical properties, pH and ionic strength of the measurement system, and the kinds and concentrations of substances existing together.

The concentration of the reaction accelerator can be experimentally determined in accordance with conditions of a measuring system. In general, however, flufenamic acid can may be used at about 0.01 to 100 mM; fusidic acid at about 0.01 to 10 mM; mefenamic acid, 2,2',6',2"-terpyridine and betamethasone acetate, each, at about 0.01 to 5 mM; monensin and mevinolin, each, at about 0.01 to 1 mM; and tiglic acid at about 1 to 500 mM.

Use of the above-described reaction accelerator has made it possible to reduce the amount of the enzyme, which acts upon free cholesterol as a substrate, to one severalth or to one several tenth. When the enzyme is used in the same amount, on the other hand, the reaction accelerator can shorten the reaction time.

In the above-described pretreatment by the enzyme which acts upon free cholesterol as a substrate (and also by the reaction accelerator, if needed), it is also possible to use other enzymes (with exclusion of those giving substantial influence to lipoproteins) and salts, buffers for pH regulation, surfactants (with exclusion of those giving substantial influence to lipoproteins), preservatives, proteins such as

albumin, and agents having affinity to specific lipoproteins, such as antibodies, antibiotics, saponins, lectins and polyanions to extents not causing agglutination of the specific lipoprotein, such that the action of the enzyme is adjusted without impairing the specificity of the measurement.

In the present invention, those containing the following ingredients can, therefore, be used as pretreatment agents for measuring cholesterol existing in specific lipoproteins in samples.

(Essential ingredients)

Enzymes which act upon free cholesterol as a substrate, for example, cholesterol dehydrogenase and cholesterol oxidase.

(Optional ingredients)

Reaction accelerators, for example, flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin and mevinolin.

(Other ingredients)

coenzymes such as NAD, other enzymes such as peroxidase, catalase, diaphorase and ascorbate oxidase, acids such as pyruvic acid, salts, buffers for pH regulation, surfactants giving no substantial influence on lipoproteins, preservatives, proteins such as albumin, antibodies, antibiotics, saponins, lectins, polyanions and couplers such as 4-aminoantipyrine, oxidative color

developers such as hydrogen donors, e.g., Trinder's reagent, electron acceptors such as phenazine methosulfate, and reductive color developers such as nitroblue tetrazolium.

In the present invention, cholesterol which exists in a specific lipoprotein in a sample is measured after having free cholesterol in lipoproteins consumed by the above-described pretreatment.

Any method can be used for the measurement of the cholesterol existing in the specific lipoprotein in the sample insofar as the method can measure the cholesterol existing in the specific lipoprotein by using a substance which acts upon the specific lipoprotein only.

An illustrative example of the method may comprise providing, as the substance which acts upon the specific lipoprotein, a surfactant selected from polyoxyethylene alkylene phenyl ethers or polyoxyethylene alkylene tribenzylphenyl ethers disclosed in JP 11-56395 A; adding a cholesterol measuring enzyme reagent in the presence of the substance; and then measuring the amount of cholesterol reacted in a time during which cholesterol in high density lipoprotein out of lipoproteins preferentially reacts with the cholesterol measuring enzyme reagent.

Examples of commercial products of the former surfactants, polyoxyethylene alkylene phenyl ethers, can include "Emulgen A-60" (trade name, product of Kao Corporation), while examples

of commercial products of the latter surfactants, polyoxyethylene alkylene tribenzylphenyl ethers, can include "Emulgen B66" (trade name, product of Kao Corporation).

As an alternative method, there is a method which makes use of the modified enzymes, which are disclosed on pages 305-320 of "SEIBUTSU SHIRYO BUNSEKI (ANALYSIS OF BIOLOGICAL SAMPLES)", **19**(5), as substances which act only upon specific lipoproteins, respectively. Although α-cyclodextrin sulfate and magnesium chloride are used in the method of this paper to inhibit reactions with lipoprotein fractions other than HDL, the use of the above-described pretreatment method of this invention makes it no longer necessary to use such substances.

Except for the use of the substance which acts upon the specific cholesterol, the method for the measurement of cholesterol existing in the specific lipoprotein can be practiced by using reagents employed in conventional cholesterol-measuring methods. Examples of ingredients which may be contained in reagents to be used can include enzymes such as cholesterol esterase, cholesterol oxidase, cholesterol dehydrogenase, isocitrate dehydrogenase, diaphorase and peroxidase, color developers, coenzymes, electron acceptors, proteins (albumin, etc.), preservatives, surfactants, salts, acids, and buffers for pH regulation.

As surfactants out of the above-described ingredients, both ionic and nonionic surfactants are usable. Illustrative are polyoxyethylene alkyl ethers, polyoxyethylene alkylphenyl

ethers, polyoxyethylene-polyoxypropylene condensate, polyoxyethylene alkyl ether sulfates, alkylbenzenesulfonate salts, and bile acid salts. The amount of the surfactant to be used varies depending on the compound. The surfactant may however be used in 0.0001% to 5%, preferably in 0.001% to 5%, although no particular limitation is imposed thereon.

No particular limitation is imposed on the buffers. Conventional buffers such as Good's buffer, phosphate buffer, Tris buffer and phthalate buffer are usable. The buffer may be used at 0.005 M to 2 M, preferably 0.01 M to 1 M, although no particular limitation is imposed thereon.

The method for quantitating cholesterol in a specific lipoprotein fraction by the present invention typically comprises firstly adding a pretreatment agent, which acts upon free cholesterol only, into a measureing sample and causing the pretreatment agent to act upon the sample, and then adding and mixing a cholesterol measuring reagent (hereafter called a "quantitation reagent"), which contains a substance capable of acting upon the specific lipoprotein and a reagent employed for a conventional cholesterol-measuring method, to measure the amount of cholesterol in the specific lipoprotein fraction.

Specific examples can include, but are not limited to, a method which comprises mixing cholesterol dehydrogenase and a coenzyme (NAD) with a sample and then adding a cholesterol-measuring reagent which comprises cholesterol esterase and cholesterol oxidase; a method which comprises

mixing cholesterol dehydrogenase and NAD with a sample and then adding a cholesterol-measuring reagent which comprises cholesterol esterase; a method which comprises mixing a sample and cholesterol oxidase together with peroxidase, 4-amino antipyrine or catalase and then adding a cholesterol-measuring reagent which comprises cholesterol esterase; and a method which comprises mixing a sample and cholesterol oxidase together with peroxidase, 4-aminoantipyrine, etc. and then adding a cholesterol-measuring reagent which comprises cholesterol esterase, cholesterol dehydrogenase and NAD.

Examples of the method for measuring cholesterol in a specific lipoprotein fraction can include a method making combined use of cholesterol esterase and cholesterol oxidase as an enzyme reagent and a method making combined use of cholesterol esterase and cholesterol dehydrogenase, although known enzyme assays are all usable.

In the present invention, the enzyme for use in the first reaction as the pretreatment reaction and the enzyme for use in the measurement of cholesterol as the quantitation method through the second reaction may be either the same or different. Further, the enzyme may be used in an excess amount in the first reaction and may also be used in the second reaction. In essence, it is only necessary to consume free cholesterol, which exists in a small amount on lipoprotein surfaces, (first reaction/pretreatment reaction) and then to bring the reaction system into a state, in which the enzyme acts only upon the

specific lipoprotein to be measured, so that most cholesterol (free cholesterol + esterified cholesterol) forming the lipoprotein can be quantitated.

Further, no particular limitation is imposed on the method for finally detecting cholesterol after the addition of such a cholesterol-measuring enzyme reagent. It is possible to use, for example, absorptiometry in which detection is conducted by combining peroxidase with a chromogen or diaphorase or an electron acceptor with a reductive color-developing reagent; or a method in which a coenzyme or hydrogen peroxide is directly detected. The coenzyme may be amplified by a coenzyme cycling system.

To practice the method of the present invention with ease, it is preferred to use a quantitation kit which is suited for measuring cholesterol in the specific lipoprotein.

Although such kits can be readily designed based on the above explanation, their examples will be described next by dividing them into those making use of cholesterol oxidase and those making use of cholesterol dehydrogenase as typical example of enzymes which act upon free cholesterol as a substrate.

[Kits making use of cholesterol oxidase]

(a) A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents (1) and (2):

(1) a first reagent comprising cholesterol oxidase and a hydrogen peroxide consuming substance (and further comprising a reaction accelerator in some instances); and

(2) a second reagent comprising a substance which acts upon the specific lipoprotein only, cholesterol esterase, and a color developer.

(b) A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents (1) and (2):

(1) a first reagent comprising cholesterol oxidase, cholesterol esterase, and a hydrogen peroxide consuming substance (and further comprising a reaction accelerator in some instances); and

(2) a second reagent comprising a substance which acts upon the specific lipoprotein only, and a color developer.

(c) A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents (1), (2) and (3):

(1) a first reagent comprising cholesterol oxidase and a hydrogen peroxide consuming substance (and further comprising a reaction accelerator in some instances);

(2) a second reagent comprising a substance which acts upon the specific lipoprotein only; and

(3) a third reagent comprising cholesterol esterase and a color developer.

In the above-described kits, the term "hydrogen peroxide consuming substance" means a substance which consumes and eliminates hydrogen peroxide produced by the reaction between cholesterol oxidase and cholesterol. Illustrative are catalase, couplers such as 4-aminoantipyrine, and

oxidative-reductive color developer agents including hydrogen donors such as Trinder's reagent.

Among these, a coupler such as 4-aminoantipyrine and a hydrogen donor such as Trinder's reagent develop a color when reacted, in combination, with hydrogen peroxide, and are usable as the color developer in the above-described reagent (2) or (3). As the reagent (1) for use in the pretreatment step according to the present invention, it is preferred to use only one of a coupler and a hydrogen donor and to have hydrogen peroxide consumed through a non-color developing reaction. Needless to say, it is also possible to subject hydrogen peroxide to a color-developing reaction and then to make an adjustment to a measured value [this adjustment can be made by subtracting the intensity of a color, which is developed by the reagent (1), from the intensity of a color developed by the reagent (2) or the reagent (3)].

[Kits making use of cholesterol dehydrogenase]

(d) A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents (1) and (2):

(1) a first reagent comprising cholesterol dehydrogenase and a coenzyme(and further comprising a reaction accelerator in some instances); and

(2) a second reagent comprising a substance, which acts upon the specific lipoprotein only, and cholesterol esterase.

(e) A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents (1) and (2):

(1) a first reagent comprising cholesterol dehydrogenase and a coenzyme(and further comprising a reaction accelerator in some instances); and

(2) a second reagent comprising a substance which acts upon the specific lipoprotein only, cholesterol oxidase, cholesterol esterase, peroxidase, and a color developer.

(f) A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents (1) and (2):

(1) a first reagent comprising cholesterol dehydrogenase, a coenzyme, and cholesterol esterase(and further comprising a reaction accelerator in some instances); and

(2) a second reagent comprising a substance which acts upon the specific lipoprotein only.

(g) A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents (1) and (2):

(1) a first reagent comprising cholesterol dehydrogenase, a coenzyme, and cholesterol esterase(and further comprising a reaction accelerator in some instances); and

(2) a second reagent comprising a substance which acts upon the specific lipoprotein only, cholesterol oxidase, peroxidase, and a color developer.

(h) A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents (1), (2) and (3):

(1) a first reagent comprising cholesterol dehydrogenase and a coenzyme(and further comprising a reaction accelerator

in some instances);

(2) a second reagent comprising a substance which acts upon the specific lipoprotein only; and

(3) a third reagent comprising cholesterol esterase.

(i) A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents (1), (2) and (3):

(1) a first reagent comprising cholesterol dehydrogenase and a coenzyme(and further comprising a reaction accelerator in some instances);

(2) a second reagent comprising a substance which acts upon the specific lipoprotein only; and

(3) a third reagent comprising cholesterol oxidase, cholesterol esterase, peroxidase, and a color developer.

(j) A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents (1) and (2):

(1) a first reagent comprising cholesterol dehydrogenase, a coenzyme, and a coenzyme reaction product consuming substance(and further comprising a reaction accelerator in some instances); and

(2) a second reagent comprising a substance, which acts upon the specific lipoprotein only, and cholesterol esterase.

(k) A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents (1) and (2):

(1) a first reagent comprising cholesterol dehydrogenase, a coenzyme, and a coenzyme reaction product consuming

substance(and further comprising a reaction accelerator in some instances); and

(2) a second reagent comprising a substance which acts upon the specific lipoprotein only, cholesterol esterase, and a color developer.

In the above-described kits making use of cholesterol dehydrogenase, the term "coenzyme reaction product consuming substance" means a substance which converts a reduced coenzyme (for example, NADH), which occurs through the reaction among cholesterol, cholesterol dehydrogenase and a coenzyme (for example, NAD), back into the original coenzyme. Illustrative is a combination of lactate dehydrogenase and pyruvic acid (substrate). In each of the above-described kits, the reaction product of the coenzyme is produced by the addition of the reagent (1). In each of the kits (d), (f), (h) and (j) out of the above-described kits, light of the same wavelength as a color developed by the addition of the reagent (1) may be measured in the measurement stage without advance consumption of the reaction product. In this case, however, it is necessary to quantitate the cholesterol in the specific lipoprotein by subtracting the intensity of a color, which is developed in the pretreatment stage in which the reagent (1) is added, from the intensity of a color developed by the reagent (2) or the reagent (3). As an alternative, it may also be possible to add beforehand the substance, which consumes the reaction product, to the reagent (1) and subsequent to consumption of

the reaction product, to add the reagent (2) or the reagent (3) for the development of a color. In this case, addition of a substance, which reduces the action of the substance which consumes the reaction product, to the reagent (2) or the reagent (3) is preferred. In each of the kits (e), (g), (I) and (k), on the other hand, it is not absolutely necessary to subtract the intensity of the color, which is developed in the pretreatment stage, from the color intensity measured in the measurement stage, because in the measurement stage, a developed color of a wavelength different from the color developed in the pretreatment stage is measured.

It is to be noted that the application of the above-mentioned reaction accelerators, such as flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin and mevinolin, is limited neither to the pretreatment method or agent of the present invention nor the quantitation method or kit of the present invention for cholesterol in a specific lipoprotein, said quantitation method or kit making use of the pretreatment method or agent.

If a reaction accelerator such as fulfenamic acid is allowed to exist concurrently upon conducting a cholesterol quantitation method making use of an enzyme which acts upon free cholesterol as a substrate, for example, a free cholesterol quantitation method making combined use of cholesterol oxidase, peroxidase, a color developer and the like or a total cholesterol

quantitation method making combined use of cholesterol oxidase, cholesterol esterase, peroxidase, a color developer and the like, it is obviously possible to bring about advantageous effects such that the amount of the enzyme to be used, said enzyme being capable of acting upon free cholesterol as a substrate and being cholesterol oxidase in the above-exemplified method, can be reduced and the time of the enzymatic reaction can be shortened.

Further, reference to the disclosure of this specification on the cholesterol quantitation method (for example, selection of a surfactant to limit a target of a specific lipoprotein to be measured) makes it possible to more specifically design a quantitation method as desired.

Industrially Applicability

The present invention has made it possible to efficiently quantitate cholesterol in a specific fraction by simple procedures without using a polyanion or the like, to say nothing of a mechanical pretreatment such as centrifugation. As the methods of the present invention do not form a precipitate which would otherwise occur by the addition of the polyanion or the like, measuring apparatus (especially, cuvettes) and the like remain free of a tarnish and moreover, measured values also remain free of scattering. The methods according to the present invention are, therefore, superior to the conventional cholesterol measuring methods.

Further, as will be demonstrated in subsequent Examples, measurement values showing a high correlation with those obtained by the conventional precipitation method can be obtained even with respect to samples with high triglyceride levels. Therefore, the methods according to the present invention are also excellent in that they are applicable to various samples without limitation.

In addition, the use of the reaction accelerator makes it possible to use the enzyme, which acts upon free cholesterol as a substrate, in a smaller amount in the pretreatment stage.

As has been described above, the methods according to the present invention permit accurate and specific measurements of a variety of samples by simple procedures while using the samples in small quantities. Accordingly, they can be applied to various automated analyzers and are also extremely useful in the field of clinical tests.

The present invention will next be described in further detail by the Examples. It should however be borne in mind that the present invention is by no means limited to the Examples.

Example 1

With respect to each of 30 serum samples containing lipoproteins, the cholesterol in HDL was quantitated by the below-described method according to the present invention and the precipitation method, and the measurement values were compared.

(Invention method)

10 mM phosphate buffer (First Reagent; pH 8.5) (300 μL), which contained 0.1 U/mL cholesterol dehydrogenase (product of Amano Pharmaceutical Co., Ltd.), 2.5 mM NAD and 0.03% 4-aminoantipyrine, was added to each sample (3 μL) (pretreatment). About 5 minutes later, a cholesterol quantitation reagent (Second Reagent) (100 μL) - which was composed of 100 mM MES buffer (pH6) containing 1% "Emulgen B-66", 1.3 U/mL cholesterol esterase (product of Asahi Chemical Industry Co., Ltd.), 2 U/mL cholesterol oxidase (product of Asahi Chemical Industry Co., Ltd.), 5 U/mL peroxidase (product of Toyobo Co., Ltd.) and 0.04% disulfobutylmetatoluidine - was added.

Just before the addition of the Second Reagent and upon an elapsed time of five minutes after the addition, the absorbance was measured at 600 nm. From a difference in absorbance, the concentration of HDL cholesterol in the serum sample was determined (2-point method). As a calibration substance, a control serum sample with a known concentration of HDL cholesterol was used. The above procedures were conducted using "Hitachi 7150 automated analyzer ".

(Precipitation method)

"HDLC 2 'Daiichi' Precipitant" (product of Daiichi Pure Chemicals Co., Ltd.) (200 μL) was mixed with the sample (200 μL), followed by centrifugation at 3,000 rpm for 10 minutes. The supernatant (50 μL) was collected, followed by the mixing with a cholesterol quantitation reagent (3 mL) composed of 100

mM MES buffer (pH6.5) containing 1% Triton X-100, 1 U/mL cholesterol esterase, 1 U/mL cholesterol oxidase, 5 U/mL peroxidase, 0.04% disulfobutylmetatoluidine and 0.04% 4-aminoantipyrine. After the resulting mixture was incubated at 37℃ for 10 minutes, its absorbance at 600 nm was measured to determine the concentration of the cholesterol in HDL.

(Results)

The results are shown in Table 1 and FIG. 1.

Table 1

Sample No.	Precipitation method (mg/dL)	Invention method (mg/dL)	Sample No.	Precipitation method (mg/dL)	Invention method (mg/dL)
1	73	72	16	54	54
2	39	39	17	45	47
3	53	52	18	60	59
4	54	54	19	50	52
5	57	58	20	58	56
6	75	71	21	38	39
7	51	51	22	56	55
8	52	50	23	35	37
9	43	43	24	29	31
10	58	58	25	63	60
11	59	59	26	51	50
12	49	51	27	33	36
13	44	46	28	52	51
14	70	65	29	65	63
15	35	38	30	47	49

As is readily envisaged from the results, the invention method, despite the omission of a polyanion or the like, showed an extremely good correlation with the conventional precipitation method.

Example 2

Measurements were conducted by another method of the present invention, which was similar to the invention method conducted in Example 1 except that in the first reagent, cholesterol dehydrogenase, NAD and the phosphate buffer were replaced by 5 U/mL cholesterol oxidase (product of Toyobo Co., Ltd.), 5 U/mL peroxidase (product of Toyobo Co., Ltd.) and 100 mM MES buffer (pH 6). The measurement values were compared with those obtained by the precipitation method in Example 1.

(Results)

The results are shown in Table 2 and FIG. 2.

Table 2

Sample No.	Precipitation method (mg/dL)	Invention method (mg/dL)	Sample No.	Precipitation method (mg/dL)	Invention method (mg/dL)
1	73	73	16	54	54
2	39	38	17	45	47
3	53	52	18	60	61
4	54	56	19	50	50
5	57	57	20	58	55
6	75	74	21	38	37
7	51	52	22	56	56
8	52	50	23	35	35
9	43	44	24	29	29
10	58	58	25	63	61
11	59	57	26	51	52
12	49	51	27	33	33
13	44	45	28	52	52
14	70	69	29	65	66
15	35	37	30	47	46

As is readily envisaged from the results, the invention method, despite the omission of a polyanion or the like, showed an extremely good correlation with the conventional precipitation method.

Example 3

Using the reagents of Example 1 and Example 2, five serum samples of different triglyceride levels were measured. The measurement values were then compared with those obtained by the precipitation method. The results are shown in Table 3.

Table 3

	Precipitation method (mg/dL)	Invention method in Example 1 (mg/dL)	Invention method in Example 2 (mg/dL)	Triglyceride level (mg/dL)
Sample A	47	49	49	198
Sample B	49	50	49	301
Sample C	26	27	24	742
Sample D	60	61	61	517
Sample E	37	40	36	428

As is shown in Table 3, measurement values of comparable levels with those obtained by the conventional method were also obtained by the present invention with respect to the samples of the high triglyceride levels.

Example 4

Measurements were conducted in a similar manner as in Example 2 except that in the first reagent, 5 U/mL cholesterol oxidase was changed to give reagent compositions of the ingredient concentrations and combinations shown below in Table 4. The measurement values were compared with those obtained by the precipitation method and also with those obtained by the invention method (standard test system) of Example 2. Incidentally, as a second reagent, the same reagent as the second reagent employed in Example 1 was used. The results are shown in Table 5.

(Compositions of testing reagents)

Table 4

Test system	Contents of composition
Standard	Cholesterol oxidase (5 U/mL)
A	Cholesterol oxidase (1 U/mL)
B	Flufenamic acid + cholesterol oxidase (0.15 mM) (1 U/mL)
C	Mefenamic acid + cholesterol oxidase (0.1 mM) (1 U/mL)
D	2,2',6',2"-terpyridine + cholesterol oxidase (0.5 mM) (1 U/mL)
E	Tiglic acid + cholesterol oxidase (50 mM) (1 U/mL)
F	Fusidic acid + cholesterol oxidase (0.1 mM) (1 U/mL)
G	Betamethasone acetate + cholesterol oxidase (0.2 mM) (1 U/mL)
H	Monensin + cholesterol oxidase (0.2 mM) (1 U/mL)
I	Mevinolin + cholesterol oxidase (0.05 mM) (1 U/mL)

(Results)

Table 5

Sample	Precipitation method (mg/dL)	Test system (mg/dL)									
		Standard	A	B	C	D	E	F	G	H	I
1	80	77	72	77	68	76	74	74	74	74	76
2	76	74	72	74	64	73	71	73	74	74	73
3	75	72	70	72	66	71	70	70	70	71	71
4	71	72	71	70	66	69	69	71	69	71	72
5	71	70	70	69	61	68	67	68	70	69	70
6	71	70	67	70	63	68	68	67	69	70	68
7	69	66	63	66	61	65	65	65	64	65	66
8	67	69	70	68	60	68	67	66	69	68	68
9	66	65	65	65	59	65	64	63	65	65	65
10	65	65	64	65	58	65	64	62	64	65	63
11	57	58	56	57	54	57	56	57	57	58	57
12	56	56	55	55	49	55	54	53	55	55	55
13	54	55	54	55	50	54	53	53	53	54	54
14	53	54	54	52	46	53	52	52	54	52	53
15	52	53	52	51	47	52	51	49	52	51	52
16	51	53	51	50	46	50	51	49	51	51	51
17	49	50	48	48	44	47	48	47	48	48	49
18	47	48	48	46	41	46	46	45	47	47	47
19	45	46	48	44	38	46	43	45	47	47	46
20	47	47	49	45	40	46	45	45	48	47	47
21	42	44	44	43	39	43	42	41	43	44	43
22	39	42	43	41	37	41	41	39	41	41	41
23	32	35	36	33	31	36	34	32	34	34	33
24	18	20	22	19	17	23	19	18	21	20	19
25	40	42	42	41	38	45	41	40	41	42	41
Correlation coef.	-	0.996	0.990	0.998	0.992	0.995	0.997	0.997	0.994	0.995	0.997
Slope		0.905	0.838	0.941	0.832	0.856	0.888	0.915	0.877	0.891	0.917
Intercept		5.6	8.7	2.6	3.4	7.5	4.6	2.8	6.3	5.7	4.1

When the amount of cholesterol oxidase was reduced to one fifth (the test system A) compared with the standard test system (Example 2), the correlation coefficient slightly declined and the value of intercept slightly increased. When the reaction accelerator was used, however, results substantially comparable with those of the standard test system were obtained even when the amount of cholesterol oxidase was one fifth. It has hence become evident from these results that the use of a reaction accelerator makes it possible to reduce the amount of cholesterol oxidase to be used.

Example 5

Reagents J to L shown below in Table 6 were prepared, which commonly contained 1.25 U/mL peroxidase (product of Toyobo Co., Ltd.), 0.01% 4-aminoantipyrine, 0.02% disulfo butyl-m-toluidine and 50 mM NaCl and were different from each other in the kind and pH of buffer and the concentrations of cholesterol oxidase (product of Toyobo Co., Ltd.) and fulfenamic acid (product of Sigma Chemical Co.).

Table 6

Reagent	① Buffer (pH) ② Concentration of cholesterol oxidase ③ Concentration of fulfenamic acid
J	① 50 mM Bis-Tris (pH 6.0) ② 0.5, 1.0, 2.5, 5.0 U/mL ③ 0, 0.01, 0.05, 0.1 mM
K	① 50 mM PIPES (pH 7.0) ② 0.5, 1.0, 2.5, 5.0 U/mL ③ 0, 0.1, 0.5, 1.0 mM
L	① 50 mM MOPS (pH 8.0) ② 0.5, 1.0, 2.5, 5.0 U/mL ③ 0, 1.0, 5.0, 10.0 mM

Reagents J to L (300 μL) were separately added to aliquots (3 μL) of each serum sample. After the resultant mixtures were incubated at 37℃ for 5 minutes, their absorbances were measured at 600 nm. The above procedures were conducted using the Hitachi 7150 automated analyzer.

Four serum samples were measured with Reagents J to L.

With respect to each of Reagents J to L, relative absorbances were calculated for the individual concentrations of cholesterol oxidase and fulfenamic acid by assuming that the absorbance obtained with a reagent containing 5.0 U/mL cholesterol oxidase and 0 mM fulfenamic acid was 100.

(Results)

Results, which had been obtained by averaging the relative absorbances of the four samples, are presented in FIG. 3, in

which "COD" stands for cholesterol oxidase.

As is readily appreciated from the results, the relative absorbance increased depending upon the concentration of fulfenamic acid irrespective of the pH. It has, therefore, been confirmed that the use of the reaction accelerator makes it possible to reduce the amount of cholesterol oxidase to be used.

It has also become clear that the reaction accelerator is also usable in a method for the measurement of free cholesterol or total cholesterol, which makes use of an enzyme which acts upon free cholesterol as a substrate.

Claims

1. (Amended) A method for pretreating a sample, which contains various lipoproteins, prior to measuring cholesterol existing in specific one of said lipoproteins in said sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample to consume only said free cholesterol in advance under conditions that said lipoproteins remain substantially unchanged.

2. (Amended) A method for pretreating a sample, which contains various lipoproteins, prior to measuring cholesterol existing in specific one of said lipoproteins in said sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample to consume only said free cholesterol in advance under conditions that said lipoproteins remain substantially unchanged.

3. A pretreatment method according to claim 1 or 2, wherein said enzyme is cholesterol oxidase or cholesterol dehydrogenase.

4. (Amended) A method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate,

to act upon said sample with said lipoprotein contained therein to consume only said free cholesterol under conditions that said lipoproteins remain substantially unchanged; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only.

5. (Amended) A method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample with said lipoprotein contained therein to consume only said free cholesterol and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only.

6. A quantitation method according to claim 4 or 5, wherein said enzyme is cholesterol oxidase and/or cholesterol dehydrogenase.

7. A quantitation method according to any one of claims 4-6, wherein said specific lipoprotein is high density lipoprotein.

8. A pretreatment agent for a sample to be measured for

cholesterol, comprising an enzyme, which acts upon free cholesterol as a substrate, and substantially no substance which acts upon lipoprotein.

9. A pretreatment agent for a sample to be measured for cholesterol, comprising an enzyme, which acts upon free cholesterol as a substrate, a reaction accelerator which is selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and substantially no substance which acts upon lipoprotein.

10. A pretreatment agent for a sample to be measured for

cholesterol, comprising an enzyme, which acts upon free cholesterol as a substrate, and substantially no cholesterol esterase.

11. A pretreatment agent for a sample to be measured for cholesterol, comprising an enzyme, which acts upon free cholesterol as a substrate, a reaction accelerator which is selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and substantially no cholesterol esterase.

12. A pretreatment agent according to any one of claims 8-10, wherein said enzyme is cholesterol dehydrogenase or cholesterol oxidase.

13. A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents:

(1) a first reagent comprising cholesterol oxidase and a hydrogen peroxide consuming substance; and

(2) a second reagent comprising a substance which acts upon said specific lipoprotein only, cholesterol esterase, and a color developer.

14. A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents:

(1) a first reagent comprising cholesterol dehydrogenase and a coenzyme; and

(2) a second reagent comprising a substance which acts upon said specific lipoprotein only, and cholesterol esterase.

15. A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents:

(1) a first reagent comprising cholesterol dehydrogenase and a coenzyme; and

(2) a second reagent comprising a substance which acts upon said specific lipoprotein only, cholesterol oxidase, cholesterol esterase, peroxidase, and a color developer.

16. A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents:

(1) a first reagent comprising cholesterol oxidase, cholesterol esterase, and a hydrogen peroxide consuming substance; and

(2) a second reagent comprising a substance which acts upon said specific lipoprotein only, and a color developer.

17. A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents:

(1) a first reagent comprising cholesterol dehydrogenase, a coenzyme, and cholesterol esterase; and

(2) a second reagent comprising a substance which acts upon said specific lipoprotein only.

18. A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents:

(1) a first reagent comprising cholesterol dehydrogenase, a coenzyme, and cholesterol esterase; and

(2) a second reagent comprising a substance which acts upon said specific lipoprotein only, cholesterol oxidase,

peroxidase, and a color developer.

19. A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents:

(1) a first reagent comprising cholesterol oxidase and a hydrogen peroxide consuming substance;

(2) a second reagent comprising a substance which acts upon said specific lipoprotein only; and

(3) a third reagent comprising cholesterol esterase and a color developer.

20. A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents:

(1) a first reagent comprising cholesterol dehydrogenase and a coenzyme;

(2) a second reagent comprising a substance which acts upon said specific lipoprotein only; and

(3) a third reagent comprising cholesterol esterase.

21. A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents:

(1) a first reagent comprising cholesterol dehydrogenase and a coenzyme;

(2) a second reagent comprising a substance which acts upon said specific lipoprotein only; and

(3) a third reagent comprising cholesterol oxidase, cholesterol esterase, peroxidase, and a color developer.

22. A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents:

(1) a first reagent comprising cholesterol dehydrogenase, a coenzyme, and a coenzyme reaction product consuming substance; and

(2) a second reagent comprising a substance which acts upon said specific lipoprotein only, and cholesterol esterase.

23. A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents:

(1) a first reagent comprising cholesterol dehydrogenase, a coenzyme, and a coenzyme reaction product consuming substance; and

(2) a second reagent comprising a substance which acts upon said specific lipoprotein only, cholesterol esterase, and a color developer.

24. A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents:

(1) a first reagent comprising (a) cholesterol oxidase, (b) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (c) a hydrogen peroxide consuming substance; and

(2) a second reagent comprising a substance which acts upon said specific lipoprotein only, cholesterol esterase, and a color developer.

25. A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents:

(1) a first reagent comprising (a) cholesterol

dehydrogenase, (b) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (c) a coenzyme; and

(2) a second reagent comprising a substance which acts upon said specific lipoprotein only, and cholesterol esterase.

26. A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents:

(1) a first reagent comprising (a) cholesterol oxidase, (b) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, (c) cholesterol esterase, and (d) a hydrogen peroxide consuming substance; and

(2) a second reagent comprising a substance, which acts upon said specific lipoprotein only, and a color developer.

27. A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents:

(1) a first reagent comprising (a) cholesterol dehydrogenase, (b) a coenzyme, (c) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (d) cholesterol esterase; and

(2) a second reagent comprising a substance which acts upon said specific lipoprotein only.

28. A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents:

(1) a first reagent comprising (a) cholesterol dehydrogenase, (b) a coenzyme, (c) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (d) cholesterol esterase; and

(2) a second reagent comprising a substance which acts upon said specific lipoprotein only, cholesterol oxidase, peroxidase, and a color developer.

29. A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents:

(1) a first reagent comprising (a) cholesterol oxidase, (b) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (c) a hydrogen peroxide consuming substance;

(2) a second reagent comprising a substance which acts upon said specific lipoprotein only; and

(3) a third reagent comprising cholesterol esterase and a color developer.

30. A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents:

(1) a first reagent comprising (a) cholesterol dehydrogenase, (b) a reaction accelerator selected from

flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (c) a coenzyme;

(2) a second reagent comprising a substance which acts upon said specific lipoprotein only; and

(3) a third reagent comprising cholesterol esterase.

31. A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents:

(1) a first reagent comprising (a) cholesterol dehydrogenase, (b) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (c) a coenzyme;

(2) a second reagent comprising a substance which acts upon said specific lipoprotein only; and

(3) a third reagent comprising cholesterol oxidase, cholesterol esterase, peroxidase, and a color developer.

32. A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents:

(1) a first reagent comprising (a) cholesterol dehydrogenase, (b) a coenzyme, (c) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (d) coenzyme reaction product consuming substance; and

(2) a second reagent comprising a substance which acts

upon said specific lipoprotein only, and cholesterol esterase.

33. A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents:

(1) a first reagent comprising (a) cholesterol dehydrogenase, (b) a coenzyme, (c) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (d) coenzyme reaction product consuming substance; and

(2) a second reagent comprising a substance which acts upon said specific lipoprotein only, cholesterol esterase, and a color developer.

34. A reaction accelerator for an enzyme capable of acting upon free cholesterol as a substrate, which is selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin.

35. A reaction accelerator according to claim 34, wherein said enzyme is cholesterol oxidase or cholesterol dehydrogenase.

36. A method for quantitating free cholesterol, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act.

37. A method for quantitating total cholesterol, which comprises causing at least an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act.

[Document Name] Drawings

[FIG. 1]



09/926818

[FIG. 2]



09/926818

(FIG. 3)



Declaration and Power of Attorney For Patent Application

特許出願宣言書及び委任状

Japanese Language Declaration

日本語宣言書

下記の氏名の発明者として、私は以下の通り宣言します。

As a below named inventor, I hereby declare that:

私の住所、私書箱、国籍は下記の私の氏名の後に記載された通りです。

My residence, post office address and citizenship are as stated next to my name.

下記の名称の発明に関して請求範囲に記載され、特許出願している発明内容について、私が最初かつ唯一の発明者（下記の氏名が一つの場合）もしくは最初かつ共同発明者（下記の名称が複数の場合）であると信じています。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled.

METHOD OF PRETREATMENT OF SAMPLE FOR QUANTITATING CHOLESTEROL AND METHOD FOR QUANTITATING CHOLESTEROL IN SPECIFIC LIPOPROTEINS BY USING THE SAME

上記発明の明細書は、

the specification of which

☐ 本書に添付されています。

☐ is attached hereto.

☒ ___月___日に提出され、米国出願番号または特許協定条約国際出願番号を_____とし、
(該当する場合) _____に訂正されました。

☒ was filed on June 14,2000
as United States Application Number or
PCT International Application Number
PCT/JP00/03860 and was amended on
April 1[illegible],2001 (if applicable).

私は、特許請求範囲を含む上記訂正後の明細書を検討し、内容を理解していることをここに表明します。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

私は、連邦規則法典第37編第1条56項に定義されるとおり、特許資格の有無について重要な情報を開示する義務があることを認めます。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

Japanese Language Declaration
(日本語宣言書)

私は、米国法典第35編119条（a）-（d）項又は365条（b）項に基づき下記の、米国以外の国の少なくとも一ヵ国を指定している特許協力条約365（a）項に基づく国際出願、又は外国での特許出願もしくは発明者証の出願についての外国優先権をここに主張するとともに、優先権を主張している、本出願の前に出願された特許または発明者証の外国出願を以下に、枠内をマークすることで、示しています。

I hereby claim foreign priority under Title 35, United States Code, Section 119 (a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s) 外国での先行出願			Priority Claimed 優先権主張	
174624/1999	JAPAN	21/June/1999	☒	☐
(Number) (番号)	(Country) (国名)	(Day/Month/Year Filed) (出願年月日)	Yes はい	No いいえ
026737/2000	JAPAN	3/February/2000	☒	☐
(Number) (番号)	(Country) (国名)	(Day/Month/Year Filed) (出願年月日)	Yes はい	No いいえ

私は、第35編米国法典119条（e）項に基づいて下記の米国特許出願規定に記載された権利をここに主張いたします。

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

(Application No.) (出願番号)	(Filing Date) (出願日)	(Application No.) (出願番号)	(Filing Date) (出願日)

私は、下記の米国法典第35編120条に基づいて下記の米国特許出願に記載された権利、又は米国を指定している特許協力条約365条（c）に基づく権利をここに主張します。また、本出願の各請求範囲の内容が米国法典第35編112条第1項又は特許協力条約で規定された方法で先行する米国特許出願に開示されていない限り、その先行米国出願書提出日以降で本出願書の日本国内または特許協力条約国際提出日までの期間中に入手された、連邦規則法典第37編1条56項で定義された特許資格の有無に関する重要な情報について開示義務があることを認識しています。

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of application.

(Application No.) (出願番号)	(Filing Date) (出願日)	(Status: Patented, Pending, Abandoned) (現況：特許許可済、係属中、放棄済)
(Application No.) (出願番号)	(Filing Date) (出願日)	(Status: Patented, Pending, Abandoned) (現況：特許許可済、係属中、放棄済)

私は、私自信の知識に基づいて本宣言書中で私が行なう表明が真実であり、かつ私の入手した情報と私の信じるところに基づく表明が全て真実であると信じていること、さらに故意になされた虚偽の表明及びそれと同等の行為は米国法典第18編第1001条に基づき、罰金または拘禁、もしくはその両方により処罰されること、そしてそのような故意による虚偽の声明を行なえば、出願した、又は既に許可された特許の有効性が失われることを認識し、よってここに上記のごとく宣誓を致します。

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Japanese Language Declaration
(日本語宣言書)

委任状：私は下記の発明者として、本出願に関する一切の手続きを米特許商標局に対して遂行する弁理士または代理人として、下記の者を指名いたします。
(弁護士、または代理人の指名及び登録番号を明記のこと)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: *(list name and registration number)*

022850

書類送付先

Send Correspondence to:

022850

直接電話連絡先：（名前及び電話番号）

Direct Telephone Calls to: (name and telephone number)

(703) 413-3000

単独発明者または第一の共同発明者の氏名	Full name of sole or first joint inventor Mitsuhiro NAKAMURA
発明者の署名　日付	Inventor's signature　Date Mitsuhiro Nakamura　December 7,2001
住所	Residence c/oDAIICHI PURE CHEMICALS CO., LTD.3-1,Koyodai 3-chome,Ryugasaki-shi, Ibaraki 301-0852,JAPAN
国籍	Citizenship JAPAN
郵便の宛先	Post Office Address (same as above)
第二の共同発明者の氏名	Full name of second joint inventor, if any Yuriko TANIGUCHI
第二の共同発明者の署名　日付	Second joint Inventor's signature　Date Yuriko Taniguchi　December 7,2001
住所	Residence c/oDAIICHI PURE CHEMICALS CO., LTD.3-1,Koyodai 3-chome,Ryugasaki-shi, Ibaraki 301-0852,JAPAN
国籍	Citizenship JAPAN
郵便の宛先	Post Office Address (same as above)

(第三以降の共同発明者についても同様に記載し、署名すること)

(Supply similar information and signature for third and subsequent joint inventors.)

Japanese Language Declaration
(日本語宣言書)

第三の共同発明者の氏名		Full name of third joint inventor, if any Mitsuhisa MANABE
第三の共同発明者の署名	日付	Third joint Inventor's signature Mitsuhisa Manabe Date December 7,2001
住所		Residence c/oDAIICHI PURE CHEMICALS CO., LTD.3-1,Koyodai 3-chome,Ryugasaki-shi, Ibaraki 301-0852,JAPAN
国籍		Citizenship JAPAN
郵便の宛先		Post Office Address (same as above)

第四の共同発明者の氏名		Full name of fourth joint inventor, if any Mitsuaki YAMAMOTO
第四の共同発明者の署名	日付	Fourth joint Inventor's signature Mitsuaki Yamamoto Date December 7,2001
住所		Residence c/o DAIICHI PURE CHEMICALS CO., LTD.3-1,Koyodai 3-chome,Ryugasaki-shi,Ibaraki 301-0852 JAPAN
国籍		Citizenship JAPAN
郵便の宛先		Post Office Address (same as above)

第五の共同発明者の氏名		Full name of fifth joint inventor, if any
第五の共同発明者の署名	日付	Fifth joint Inventor's signature Date
住所		Residence
国籍		Citizenship
郵便の宛先		Post Office Address

第六の共同発明者の氏名		Full name of sixth joint inventor, if any
第六の共同発明者の署名	日付	Sixth joint Inventor's signature Date
住所		Residence
国籍		Citizenship
郵便の宛先		Post Office Address

(第六またはそれ以降の共同発明者に対しても同様な情報および署名を提供すること。)

(Supply similar information and signature for third and subsequent joint inventors.)